https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index en-au 5 Defining reliable disability outcomes in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13691 Wed 11 Apr 2018 17:01:07 AEST ]]> Geographical variations in sex ratio trends over time in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13697 Wed 11 Apr 2018 16:44:40 AEST ]]> Predictors of disability worsening in clinically isolated syndrome https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:13693 Wed 11 Apr 2018 14:32:54 AEST ]]> Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> Predictors and dynamics of postpartum relapses in women with multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:17471 Sat 24 Mar 2018 08:04:07 AEDT ]]> Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> Seasonal variation of relapse rate in multiple sclerosis is latitude dependent https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> Risk of relapse phenotype recurrence in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> Defining secondary progressive multiple sclerosis https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]>